Cell Dissociation Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.53 Billion |
| Market Size (2029) | USD 1.08 Billion |
| CAGR (2024 - 2029) | 15.17 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cell Dissociation Market Analysis
The Cell Dissociation Market size is estimated at USD 0.53 billion in 2024, and is expected to reach USD 1.08 billion by 2029, growing at a CAGR of 15.17% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market studied. As most pharmaceutical companies focused on therapeutics for COVID-19 infection, the production of cell dissociation enzymes decreased significantly during the pandemic. However, the market has reached its pre-pandemic nature and is expected to witness strong growth over the forecast period.
Key factors responsible for the market growth include increasing R&D activities in biopharmaceutical companies and favorable funding for cancer research globally.
The increase in research and development spending in the biopharmaceutical sector aided in the market's growth. For example, according to 'The Pharmaceutical Industry and Global Health Facts and Figures 2021' published by the International Federation of Pharmaceutical Manufacturers & Associations, the annual research and development spending of the biopharmaceutical industry has been 7.3 times greater than that of the aerospace and defense, industries, 6.5 times more than that the chemicals industry, and 1.5 times more than that of the software and computer services industry. The report further stated that in, 2022 over USD 202 billion was estimated to be spent worldwide on biopharmaceutical research and development. Hence, with strong investments in R&D activities and a pipeline of therapeutics under development, cell dissociation is expected to grow significantly.
Various companies are investing in the research and development of biopharmaceuticals. For instance, in September 2022, Marinus Pharmaceuticals exercised the first contract option by the Biomedical Advanced Research and Development Authority (BARDA) valued at approximately USD 12.3 million, to support the United States onshoring of the manufacturing capabilities for ganaxolone. Furthermore, the new investments in the research and development of biologics by the major market players increase the research activity in producing new biologics. They are expected to drive the market to grow. For instance, in September 2022, Novartis invested in next-generation biotherapeutics to grow its biologics manufacturing and development operations. Hence, with huge R&D investments, the market studied is expected to grow strongly in the coming years.
However, the high cost of tissue- and cell-based procedures is expected to restrain the market growth over the forecast period.
Cell Dissociation Market Trends
Pharmaceutical and Biotechnology Companies Segment is Expected to Witness a Healthy Growth Over the Forecast Period
The increasing focus of biopharmaceutical companies on new drug development and increasing R&D is augmenting the demand for cell dissociation across such companies.
In recent years, there has been a growing demand for biopharmaceuticals due to surging cases of cancer and other life-threatening diseases. There has been a rise in the demand for targeted therapies in recent years. For instance, an article by Pharmaceutical Technology, updated in August 2021, indicated that innovative, novel biologics help in the growth of the biopharmaceutical market, as improved processes and technological developments are aiding in changing the future of manufacturing. Manufacturers of biosimilars are offering less expensive alternatives to many of the monoclonal antibody medications that generate the most revenue in the market at reduced clinical and R&D expenditures.
Also, an article from PubMed published in March 2022 indicated an increase in the demand for biopharmaceuticals, which had prompted the emergence of a business model called 'contract development manufacturing organization (CDMO)' that aids in the development and manufacturing processes. The CDMOs could efficiently manufacture larger volumes of the required biopharmaceutical product, meeting the increasing demands.
Thus, owing to these factors, the segment is expected to grow significantly over the forecast period.
North America is Expected to Hold Significant Share of the Market
The cell dissociation market in the North American region is expected to witness significant growth owing to factors such as the highly advanced biopharmaceutical industry, which allows extensive R&D of novel therapeutics and increasing company investment to develop new therapies.
According to the Cancer Facts & Figures 2023 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed and 0.6 million cancer deaths in the United States (US) in 2023. In addition, in the US, the population aged 65 or more was 54.1 million (16% of the total population) in 2019, estimated at 21.6% by 2040. Hence, the prevalence of chronic diseases coupled with the increasing geriatric population in the country is anticipated to create more opportunities for developing new biopharmaceuticals, driving the studied market growth.
Moreover, the incidence of Cancer, cardiovascular diseases (CVDs), and diabetes creates demand for new biopharmaceuticals. For instance, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with Cancer in 2021. Also, according to the estimates, the death rates for the three leading cancer types in 2021 were lung cancer (25%), colorectal Cancer (11%), and pancreatic Cancer (7%). With these estimates, it was reported that Cancer remained one of Canada's leading causes of death in 2021. Thus creating opportunities for new therapies in the country and driving the studied market growth.
Cell Dissociation Industry Overview
The cell dissociation market studied is moderately competitive, and several local and international players are posing intense competition across various geographies. Most of this market's key players have a good presence in the North America and Europe region. Some European countries, Germany, France, and Italy, are where biotechnology companies are trying to establish their R&D plants. Similarly, the United States is a country where all the companies are generating large revenue due to the high adoption of the technologies and increasing use of cell dissociation.
Cell Dissociation Market Leaders
F. Hoffmann-La Roche Ltd.
Merck KGaA
Thermo Fisher Scientific
GE Healthcare
Becton, Dickinson and Company
*Disclaimer: Major Players sorted in no particular order
Cell Dissociation Market News
- September 2022: Marinus Pharmaceuticals exercised the first contract option by the Biomedical Advanced Research and Development Authority (BARDA), valued at approximately USD 12.3 million, to support the United States onshoring of the manufacturing capabilities for ganaxolone.
- March 2022: ThermoFisher Scientific Inc. made a USD 97 million investment to extend its clinical research facilities in Richmond, Virginia.
Cell Dissociation Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Activities in Biopharmaceutical Companies
4.2.2 Favourable Funding Scenario for Cancer Research
4.3 Market Restraints
4.3.1 High cost of Tissue- and Cell-based Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Enzymatic Dissociation Products
5.1.2 Non-enzymatic Dissociation Products
5.1.3 Instruments and Accessories
5.2 By Tissue
5.2.1 Connective Tissue
5.2.2 Epithelial Tissue
5.2.3 Other Tissues
5.3 By End-User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Research and Academic Institutes
5.3.3 Other End-Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 American Type Culture Collection
6.1.2 Becton, Dickinson and Company
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 GE Healthcare
6.1.5 Himedia Laboratories
6.1.6 Merck KGaA
6.1.7 Miltenyi Biotec
6.1.8 Pan-Biotech
6.1.9 Stemcell Technologies
6.1.10 Thermo Fisher Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cell Dissociation Industry Segmentation
Cell dissociation refers to the act of separating adherent cell monolayers into single-cell suspensions. The cell dissociation process has tremendous application in regenerative medicine and stem cell research. The cell dissociation products are either enzyme-based or non-enzymatic buffers. The Cell Dissociation Market is segmented by Product (Enzymatic Dissociation Products, Non-Enzymatic Dissociation Products, Instruments, and Accessories), Tissue (Connective Tissue, Epithelial Tissue, and Other Tissues), End-User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value in USD for the above segments.
| By Product | |
| Enzymatic Dissociation Products | |
| Non-enzymatic Dissociation Products | |
| Instruments and Accessories |
| By Tissue | |
| Connective Tissue | |
| Epithelial Tissue | |
| Other Tissues |
| By End-User | |
| Pharmaceutical and Biotechnology Companies | |
| Research and Academic Institutes | |
| Other End-Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cell Dissociation Market Research FAQs
How big is the Cell Dissociation Market?
The Cell Dissociation Market size is expected to reach USD 0.53 billion in 2024 and grow at a CAGR of 15.17% to reach USD 1.08 billion by 2029.
What is the current Cell Dissociation Market size?
In 2024, the Cell Dissociation Market size is expected to reach USD 0.53 billion.
Who are the key players in Cell Dissociation Market?
F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific, GE Healthcare and Becton, Dickinson and Company are the major companies operating in the Cell Dissociation Market.
Which is the fastest growing region in Cell Dissociation Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cell Dissociation Market?
In 2024, the North America accounts for the largest market share in Cell Dissociation Market.
What years does this Cell Dissociation Market cover, and what was the market size in 2023?
In 2023, the Cell Dissociation Market size was estimated at USD 0.45 billion. The report covers the Cell Dissociation Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cell Dissociation Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cell Dissociation Industry Report
Statistics for the 2024 Cell Dissociation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cell Dissociation analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
